Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults
Author:
Affiliation:
1. Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy
Publisher
Informa UK Limited
Subject
Virology,Infectious Diseases,Microbiology (medical),Microbiology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14787210.2018.1544491
Reference89 articles.
1. KAPOSI'S SARCOMA IN HOMOSEXUAL MEN—A REPORT OF EIGHT CASES
2. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada
3. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world
4. Chronic illness burden and quality of life in an aging HIV population
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Two cases of drug induced hypersensitivity to dolutegravir-rilpivirine fixed-dose combination: A case report;International Journal of Risk & Safety in Medicine;2023-05-04
2. Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV;Expert Review of Anti-infective Therapy;2022-06-13
3. No decrease in CD4/CD8 ratio after 36 months therapy in patients switched to dual regimens containing rilpivirine;Enfermedades Infecciosas y Microbiología Clínica;2021-02
4. No decrease in CD4/CD8 ratio after 36 months therapy in patients switched to dual regimens containing rilpivirine;Enfermedades infecciosas y microbiologia clinica (English ed.);2021-02
5. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens;Current Opinion in Pharmacology;2020-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3